Latest & greatest articles for opioid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on opioid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on opioid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for opioid

81. Opioids for chronic non-cancer pain in children and adolescents.

Opioids for chronic non-cancer pain in children and adolescents. BACKGROUND: Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The World Health Organization guidelines for pharmacological treatments for children's persisting pain acknowledge that pain in children is a major public health concern of high significance in most parts of the world. While in the past, pain was largely dismissed and was frequently left untreated (...) , views on children's pain have changed over time, and relief of pain is now seen as importantWe designed a suite of seven reviews on chronic non-cancer pain and cancer pain (looking at antidepressants, antiepileptic drugs, non-steroidal anti-inflammatory drugs, opioids, and paracetamol as priority areas) in order to review the evidence for children's pain utilising pharmacological interventions in children and adolescents.As the leading cause of morbidity in children and adolescents in the world

Cochrane2017

82. Opioids for cancer-related pain in children and adolescents.

Opioids for cancer-related pain in children and adolescents. BACKGROUND: Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The World Health Organization (WHO) guidelines for pharmacological treatments for children's persisting pain acknowledge that pain in children is a major public health concern of high significance in most parts of the world. Views on children's pain have changed over time and relief of pain is now seen (...) as important. In the past, pain was largely dismissed and was frequently left untreated, and it was assumed that children quickly forgot about painful experiences.We designed a suite of seven reviews in chronic non-cancer pain and cancer pain (looking at antidepressants, antiepileptic drugs, non-steroidal anti-inflammatory drugs, opioids, and paracetamol) to review the evidence for children's pain using pharmacological interventions.As one of the leading causes of mortality and morbidity for children

Cochrane2017

83. Occupational Therapy Interventions to Prevent Opioid Relapse: Clinical and Cost-Effectiveness and Guidelines

Occupational Therapy Interventions to Prevent Opioid Relapse: Clinical and Cost-Effectiveness and Guidelines Occupational Therapy Interventions to Prevent Opioid Relapse: Clinical and Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Occupational Therapy Interventions to Prevent Opioid Relapse: Clinical and Cost-Effectiveness and Guidelines Occupational Therapy Interventions to Prevent Opioid Relapse: Clinical and Cost-Effectiveness and Guidelines Published on: July 10 (...) , 2017 Project Number: RB1107-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of occupational therapy interventions to prevent relapse of opioid use in patients with chronic pain or opioid dependence? What is the cost-effectiveness of occupational therapy interventions to prevent relapse of opioid use in patients with chronic pain or opioid dependence? What are the evidence-based guidelines

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

84. Opioids for cancer pain - an overview of Cochrane reviews.

Opioids for cancer pain - an overview of Cochrane reviews. BACKGROUND: Pain is a common symptom with cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain that can have a major negative impact on their quality of life. Opioid (morphine-like) drugs are commonly used to treat moderate or severe cancer pain, and are recommended for this purpose in the World Health Organization (WHO) pain treatment ladder. The most commonly-used opioid drugs are buprenorphine (...) , codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, tramadol, and tapentadol. OBJECTIVES: To provide an overview of the analgesic efficacy of opioids in cancer pain, and to report on adverse events associated with their use. METHODS: We identified systematic reviews examining any opioid for cancer pain published to 4 May 2017 in the Cochrane Database of Systematic Reviews in the Cochrane Library. The primary outcomes were no or mild pain within 14 days of starting treatment

Cochrane2017

86. Do ?2-Adrenergic Agonists Decrease the Symptoms Associated With Opioid Withdrawal?

Do ?2-Adrenergic Agonists Decrease the Symptoms Associated With Opioid Withdrawal? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2017

87. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer 28445097 2017 04 26 2017 06 07 1527-7755 35 17 2017 Jun 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer. 1921-1928 10.1200/JCO (...) .2016.70.8453 Purpose This randomized, double-blind, multicenter study aimed to determine the dose of naldemedine, a peripherally-acting μ-opioid receptor antagonist, for future trials by comparing the efficacy and safety of three doses of naldemedine versus placebo in patients with cancer and opioid-induced constipation. Methods Patients ≥ 18 years old with cancer, an Eastern Cooperative Oncology Group performance status ≤ 2, who had been receiving a stable regimen of opioid analgesics for ≥ 2 weeks, had

EvidenceUpdates2017

88. The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine

The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International: The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine'', 1 July 2017 {1} {1} {1} | | > > > In the July issue of Prescrire International: The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |  (...)  |   |   |   |   |   |   |  Spotlight In the July issue of Prescrire International: The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine FREE DOWNLOAD In the Adverse Effects section of this issue, the cardiac risks of the cytotoxic immunosuppressant temsirolimus, used in metastatic renal cell carcinoma and mantle cell lymphoma, and the harms caused by the opioid pholcodine, still present in many cough suppressants. Full

Prescrire2017

89. [Intrathecal opioid infusion pump for chronic cancer and non-cancer pain]

[Intrathecal opioid infusion pump for chronic cancer and non-cancer pain] [Intrathecal opioid infusion pump for chronic cancer and non-cancer pain] [Intrathecal opioid infusion pump for chronic cancer and non-cancer pain] Rey-Ares L, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Rey-Ares L, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A. [Intrathecal opioid infusion pump for chronic cancer and non-cancer pain] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 514. 2017 Authors' conclusions Scarce evidence of moderate methodological quality suggests that the use of intrathecal opioids

Health Technology Assessment (HTA) Database.2017

90. The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness and Guidelines

The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness and Guidelines The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness and Guidelines The Use of Transdermal Buprenorphine Patches in Aiding in Opioid Withdrawal: Clinical Effectiveness (...) and Guidelines Published on: June 8, 2017 Project Number: RA0911-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness regarding the use of buprenorphine patches for aiding in opioid withdrawal prior to starting a patient on buprenorphine/naloxone? What are the evidence-based guidelines regarding the use of buprenorphine patches for aiding in opioid withdrawal prior to starting a patient on buprenorphine/naloxone? Key Message One non

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

93. Symproic (naldemedine) Tablets - For the treatment of opioid-induced constipation

Symproic (naldemedine) Tablets - For the treatment of opioid-induced constipation Symproic (naldemedine) Tablets U.S. Department of Health and Human Services Search FDA Submit search Symproic (naldemedine) Tablets Symproic Company: Shionogi Inc. Application No.: 208854 Approval Date: 03/23/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

FDA - Drug Approval Package2017

94. Guideline for opioid therapy and chronic noncancer pain

Guideline for opioid therapy and chronic noncancer pain Guideline for opioid therapy and chronic noncancer pain Information for… Search for Keyword: Submit , DC PhD , , MSc , , MD PhD , , MD , , PhD , , MA MISt , , MD PhD , , MD PhD , , DDS MSc , , BES , , , PT PhD , , MD MPH , , AB LLB MD , , MD PhD , , MD MSc , , MD , , MD MSc , , MD PhD , , MD MSc According to seven national surveys conducted between 1994 and 2008, 15%–19% of Canadian adults live with chronic noncancer pain. Chronic (...) noncancer pain interferes with activities of daily living, has a major negative impact on quality of life and physical function, and is the leading cause of health resource utilization and disability among working-age adults. , In North America, clinicians commonly prescribe opioids for acute pain, palliative care (in particular, for patients with cancer) and chronic noncancer pain. Canada has the second highest rate per capita of opioid prescribing in the world when measured using defined daily doses

CMA Infobase (Canada)2017

95. Alternative opioid agonists in the treatment of opioid dependence: a systematic review

Alternative opioid agonists in the treatment of opioid dependence: a systematic review Alternative opioid agonists in the treatment of opioid dependence: a systematic review - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Alternative opioid agonists in the treatment of opioid dependence: a systematic review Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle (...) Close Health in Norway Close Quality and Knowledge Close More topics Close Opioid maintenance treatment can help people with opioid dependence to improve their lives. The treatment is effective, but people often experience side effects. Sometimes it may help to change the medication used in treatment. In this review, we have looked at treatment with slow release oral morphine and levomethadone. These treatments are compared to the three medications used in Norway: buprenorphine with naloxone

Norwegian Institute of Public Health2017

96. Randomized, double-blinded, placebo-controlled trial comparing two multimodal opioid-minimizing pain management regimens following transsphenoidal surgery

Randomized, double-blinded, placebo-controlled trial comparing two multimodal opioid-minimizing pain management regimens following transsphenoidal surgery 28298041 2017 03 16 2017 03 16 1933-0693 2017 Mar 03 Journal of neurosurgery J. Neurosurg. Randomized, double-blinded, placebo-controlled trial comparing two multimodal opioid-minimizing pain management regimens following transsphenoidal surgery. 1-8 10.3171/2016.10.JNS161355 OBJECTIVE Pain control is an important clinical consideration (...) and quality-of-care metric. No studies have examined postoperative pain control following transsphenoidal surgery for pituitary lesions. The study goals were to 1) report postoperative pain scores following transsphenoidal surgery, 2) determine if multimodal opioid-minimizing pain regimens yielded satisfactory postoperative pain control, and 3) determine if intravenous (IV) ibuprofen improved postoperative pain scores and reduced opioid use compared with placebo. METHODS This study was a single-center

EvidenceUpdates2017

97. Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines

Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical Effectiveness and Guidelines Magnesium as an Alternative or Adjunct to Opioids for Chronic Pain: A Review of the Clinical

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

99. Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines

Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical (...) and Cost-Effectiveness, and Guidelines Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines Published on: April 13, 2017 Project Number: RB1083-000 Product Line: Research Type: Drugs Report Type: Summary of Abstracts Result type: Report Question What is the comparative clinical effectiveness of sustained release oral morphine (SROM) versus standard of care (i.e., methadone or buprenorphine

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

100. Strategies for the Reduction or Discontinuation of Opioids: Guidelines

Strategies for the Reduction or Discontinuation of Opioids: Guidelines Strategies for the Reduction or Discontinuation of Opioids: Guidelines | CADTH.ca Find the information you need Strategies for the Reduction or Discontinuation of Opioids: Guidelines Strategies for the Reduction or Discontinuation of Opioids: Guidelines Published on: April 5, 2017 Project Number: RB1078-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What (...) are the evidence-based guidelines regarding tapering strategies for the reduction or discontinuation of opioids? What are the evidence-based guidelines regarding switching or crossover strategies for the reduction or discontinuation of opioids? Key Message Six evidence-based guidelines were identified regarding tapering, rotating, switching, or crossover strategies for the reduction or discontinuation of opioids. Tags analgesics, opioid, drug substitution, opioid-related disorders, other miscellaneous topics

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017